Scholar Rock Holding Corporation (NasdaqGS: SRRK)
Health Care · Biotechnology · US
$42.20
0.00% today · +9.1% 1Y
Scholar Rock Holding Corporation (NasdaqGS: SRRK) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.14B and employs 289 people.
Over the last twelve months the share price has gained 9.1%, trading between 27.07 and 61.76.
Tweenvest scores Scholar Rock Holding Corporation across four factors: quality 35/100, value 69/100. Its strongest factor is value.
SRRK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.14B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.36
- Dividend yield
- —
- Beta (5Y)
- 0.62
- 52-week high
- $61.76
- 52-week low
- $27.07
- Avg volume (3M)
- —
- Shares outstanding
- 121.79M
- Employees
- 289
- Next earnings
- —
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
- ISIN
- US80706P1030
- Founded
- 2012
- Listed since
- May 25, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PTC Therapeutics, Inc.NasdaqGS: PTCT | $5.28B | $62.56 | -1.06% |
| Cogent Biosciences, Inc.NasdaqGS: COGT | $5.23B | $30.08 | -0.20% |
| Shanghai RAAS Blood Products Co., Ltd.SZSE: 002252 | $5.23B | CN¥5.32 | +5.98% |
| Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.SHSE: 603392 | $5.15B | CN¥27.34 | +3.64% |
| CRISPR Therapeutics AGNasdaqGM: CRSP | $5.06B | $50.44 | -3.65% |
| Chongqing Zhifei Biological Products Co., Ltd.SZSE: 300122 | $4.99B | CN¥13.98 | +7.46% |
| 3SBio Inc.SEHK: 1530 | $4.99B | HK$15.70 | -1.94% |
| Erasca, Inc.NasdaqGS: ERAS | $4.94B | $15.46 | +9.49% |
Figures last refreshed Oct 4, 2026.